NCT07025850View on ClinicalTrials.gov

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

May 1, 2027

Conditions
Colorectal Carcinoma
Interventions
DRUG

Digoxin

p.o. 0.5mg q.d.

DRUG

Fuquinitinib

Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.

DRUG

Tislelizumab

Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.

Trial Locations (2)

200030

Fudan University Shanghai Cancer Center, Shanghai

Unknown

Anyang Cancer Hospital, Anyang

All Listed Sponsors
collaborator

Anyang Tumor Hospital

OTHER

lead

Fudan University

OTHER

NCT07025850 - Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter